國立虎尾科技大學 |

Small Molecules in Hematology

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Small Molecules in Hematology/ edited by Uwe M. Martens.
其他作者:	Martens, Uwe M.
面頁冊數:	VIII, 294 p. 28 illus., 17 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Hematology. -
電子資源:	https://doi.org/10.1007/978-3-319-91439-8
ISBN:	9783319914398

Small Molecules in Hematology
Small Molecules in Hematology[electronic resource] /edited by Uwe M. Martens. - 3rd ed. 2018. - VIII, 294 p. 28 illus., 17 illus. in color.online resource. - Recent Results in Cancer Research,2120080-0015 ;. - Recent Results in Cancer Research,200.

Imatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib.

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. .

ISBN: 9783319914398

Standard No.: 10.1007/978-3-319-91439-8doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Small Molecules in Hematology
LDR:02808nam a22004095i 4500 001 986536
003 DE-He213
005 20200702165748.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319914398 $9 978-3-319-91439-8
024 7 $a 10.1007/978-3-319-91439-8 $2 doi
035 $a 978-3-319-91439-8
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Small Molecules in Hematology $h [electronic resource] / $c edited by Uwe M. Martens.
250 $a 3rd ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a VIII, 294 p. 28 illus., 17 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 212
505 0 $a Imatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib.
520 $a This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. .
650 0 $a Hematology. $3 645254
650 0 $a Oncology . $3 1253469
650 2 4 $a Oncology. $3 593951
700 1 $a Martens, Uwe M. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1207758
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319914381
776 0 8 $i Printed edition: $z 9783319914404
776 0 8 $i Printed edition: $z 9783030082567
830 0 $a Recent Results in Cancer Research, $x 0080-0015 ; $v 200 $3 1263334
856 4 0 $u https://doi.org/10.1007/978-3-319-91439-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)